Abstract:Background Dilated cardiomyopathy (DCM), characterized by progressive left ventricular enlargement and systolic dysfunction, is the most common type of cardiomyopathy and a leading cause of heart failure and cardiac death. Accumulating evidence underscores the critical role of genetic defects in the pathogenesis of DCM, and >250 genes have been implicated in DCM to date. However, DCM is of substantial genetic heterogeneity, and the genetic basis underpinning DCM remains elusive in most cases. Methods and Results By genome‐wide scan with microsatellite markers and genetic linkage analysis in a 4‐generation family inflicted with autosomal‐dominant DCM, a new locus for DCM was mapped on chromosome 15q13.1–q13.3, a 4.77‐cM (≈3.43 Mbp) interval between markers D15S1019 and D15S1010, with the largest 2‐point logarithm of odds score of 5.1175 for the marker D15S165 at recombination fraction (θ)=0.00. Whole‐exome sequencing analyses revealed that within the mapping chromosomal region, only the mutation in the KLF13 gene, c.430G>T (p.E144X), cosegregated with DCM in the family. In addition, sequencing analyses of KLF13 in another cohort of 266 unrelated patients with DCM and their available family members unveiled 2 new mutations, c.580G>T (p.E194X) and c.595T>C (p.C199R), which cosegregated with DCM in 2 families, respectively. The 3 mutations were absent from 418 healthy subjects. Functional assays demonstrated that the 3 mutants had no transactivation on the target genes ACTC1 and MYH7 (2 genes causally linked to DCM), alone or together with GATA4 (another gene contributing to DCM), and a diminished ability to bind the promoters of ACTC1 and MYH7 . Add, the E144X‐mutant KLF13 showed a defect in intracellular distribution. Conclusions This investigation indicates KLF13 as a new gene predisposing to DCM, which adds novel insight to the molecular pathogenesis underlying DCM, implying potential implications for prenatal prevention and precision treatment of DCM in a subset of patients. Nonstandard Abbreviations and Acronyms DCM dilated cardiomyopathy WES whole‐exome sequencing Clinical Perspective What Is New? By genome‐wide screening with microsatellite markers and genetic linkage analysis in a 4‐generation family suffering from autosomal‐dominant dilated cardiomyopathy (DCM), a new locus for DCM was mapped on chromosome 15q13.1–q13.3. A novel mutation in the KLF13 gene, c.430G>T (p.E144X), was identified by whole‐exome sequencing analysis to cosegregate with DCM in the family within the mapping chromosomal region; sequencing analyses of KLF13 in another cohort of 266 unrelated patients with DCM and their available family members revealed 2 novel mutations, c.580G>T (p.E194X) and c.595T>C (p.C199R), which cosegregated with DCM in 2 families, respectively. The 3 mutants had no transactivation on the target genes ACTC1 and MYH7 , alone or together with GATA4, and the 3 mutations showed a diminished ability to bind the promoters of ACTC1 and MYH7 ; the E144X‐mutant KLF13 showed a defect in intracellular distribution. What Are the Clinical Implications? The discovery of a new DCM‐causative gene has potential implications for antenatal prophylaxis and precise management of DCM. The DCM‐associated genetic data may be used for prognostic risk stratification of patients with DCM. Dilated cardiomyopathy (DCM), defined by left ventricular enlargement with systolic dysfunction at the exclusion of other usual clinically detectable causes responsible for impaired global contractile function, is the most prevalent form of myocardial disease in humans, with an estimated prevalence of up to 1 in 250 individuals worldwide. 1 , 2 , 3 Notably, there is a significant sex difference in the incidence of DCM, with an overall combined mean male:female sex ratio of 2.5:1. 4 DCM confers a significantly enhanced risk for heart failure, ventricular and supraventricular dysrhythmias, cardiac transplantation, and death. 5 , 6 , 7 , 8 , 9 F -Abstract Truncated-

Dilated cardiomyopathy: from epidemiologic to genetic phenotypes

Dilated cardiomyopathies and non-compaction cardiomyopathy

A Genetic Journey from Past to Future

Genetic Determinant of Familial Dilated Cardiomyopathy and Genotype-Targeted Therapeutic Strategy

Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments

Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology

Evolving concepts in dilated cardiomyopathy

Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine

DMD-Associated Dilated Cardiomyopathy: Genotypes, Phenotypes, and Phenocopies

Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences

Diagnosis, prevalence, and screening of familial dilated cardiomyopathy

Dilated cardiomyopathy and chronic cardiac inflammation: Pathogenesis, diagnosis and therapy

Atlas of the Clinical Genetics of Human Dilated Cardiomyopathy

Environmental Risk Factors Influence the Natural History of Familial Dilated Cardiomyopathy

A Comprehensive Outlook on Dilated Cardiomyopathy (DCM): State-Of-The-Art Developments with Special Emphasis on OMICS-Based Approaches

The Molecular Role of Immune Cells in Dilated Cardiomyopathy

Prevalence of Genetically Associated Dilated Cardiomyopathy: A Systematic Literature Review and Meta-Analysis

The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy

KLF13 Loss‐of‐Function Mutations Underlying Familial Dilated Cardiomyopathy

Comprehensive Clinical Characterization of Patients Diagnosed With Dilated Cardiomyopathy: A Cross-Sectional Study

Diabetic cardiomyopathy: Clinical phenotype and practice